Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 9,577 Shares

14 Jan 2026, 17:51 by Teresa Graham · The Cerbat Gem

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) CEO Yvonne Greenstreet sold 9,577 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the completion of the transaction, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. This represents a 10.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Yvonne Greenstreet also recently made the following trade(s):

On Thursday, November 13th, Yvonne Greenstreet sold 10,000 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $451.27, for a total transaction of $4,512,700.00.
On Wednesday, November 12th, Yvonne Greenstreet sold 15,650 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $453.69, for a total transaction of $7,100,248.50.

Alnylam Pharmaceuticals Stock Down 0.8%

NASDAQ:ALNY traded down $3.10 during midday trading on Wednesday, hitting $366.86. 1,250,033 shares of the company were exchanged, compared to its average volume of 1,593,122. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The company has a market capitalization of $48.47 billion, a PE ratio of 1,528.58 and a beta of 0.32. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. The company has a fifty day simple moving average of $423.39 and a 200 day simple moving average of $421.94.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds have recently made changes to their positions in ALNY. Thematics Asset Management acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $1,995,000. Teacher Retirement System of Texas increased its holdings in Alnylam Pharmaceuticals by 3.2% during the 2nd quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock worth $11,872,000 after purchasing an additional 1,123 shares during the last quarter. Generali Asset Management SPA SGR increased its holdings in Alnylam Pharmaceuticals by 6,368.0% during the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock worth $1,475,000 after purchasing an additional 3,184 shares during the last quarter. Investment Management Corp of Ontario raised its position in shares of Alnylam Pharmaceuticals by 35.4% in the 2nd quarter. Investment Management Corp of Ontario now owns 31,521 shares of the biopharmaceutical company’s stock valued at $10,279,000 after purchasing an additional 8,244 shares in the last quarter. Finally, Congress Asset Management Co. purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $54,173,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

Positive Sentiment: Needham & Company reiterated a bullish outlook and forecasted strong price appreciation for ALNY, giving investors a counterpoint to bearish views and providing potential support for the stock. Needham Bullish Forecast
Positive Sentiment: Alnylam presented at the J.P. Morgan Healthcare Conference (transcript available) — management used the forum to outline development priorities and the Alnylam 2030 growth plan, keeping the company in front of institutional investors. JPM Presentation Transcript
Neutral Sentiment: Analysis pieces are digesting the Alnylam 2030 plan and new 2026 guidance; valuation write-ups provide scenarios but do not change fundamentals immediately. These pieces are useful for longer-term investors assessing the plan vs. current multiples. Valuation After 2030 Plan
Neutral Sentiment: CEO interviews and conference coverage (video/interview links) elaborate on development goals and timelines; useful for due diligence but contain no immediate new financials. CEO Interview
Neutral Sentiment: Industry roundups from JPM/BioWorld reference Alnylam within broader biopharma Q4 revenue and guidance commentary — helpful context but not company-specific catalysts. Bioworld JPM Coverage
Neutral Sentiment: Reported short-interest data appears anomalous (shows zero shares and NaN changes), so it should not be treated as signal until corrected by exchanges. No link (data issue)
Negative Sentiment: Insider selling: CEO Yvonne Greenstreet and multiple EVPs sold shares on Jan 12–13 (CEO sale ~9,577 shares; several EVPs sold 1,510–2,780 shares each). Collectively these disclosed sales totaled roughly $7M, which markets often view as a near-term negative signal even if sales are for personal/diversification reasons. CEO SEC Filing
Negative Sentiment: Bank of America published a pessimistic price forecast for ALNY, which can weigh on sentiment among institutional and retail investors. BofA Pessimistic Forecast
Negative Sentiment: News coverage highlighted a sharp intraday sell-off (article noting ~9% drop) after the company unveiled ambitious 2026 guidance and its Alnylam 2030 plan — the market appears to be re-pricing risk around execution and near-term guidance. Coverage of the Sell-off

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Leerink Partners cut their price target on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research report on Monday, December 15th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. HC Wainwright set a $570.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, November 4th. JPMorgan Chase & Co. lowered their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating on the stock in a research report on Monday, October 13th. Finally, Piper Sandler restated an “overweight” rating and issued a $489.00 price objective (up from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Twenty-two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $490.96.

Read Our Latest Stock Analysis on ALNY

About Alnylam Pharmaceuticals

(Get Free Report)

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.